Scarica l'app Stockscreener
227.99
0.11%
-0.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$228.25
Aprire:
$228.78
Volume 24 ore:
3.53M
Relative Volume:
0.66
Capitalizzazione di mercato:
$402.76B
Reddito:
$58.33B
Utile/perdita netta:
$3.73B
Rapporto P/E:
108.50
EPS:
2.1013
Flusso di cassa netto:
$18.24B
1 W Prestazione:
-0.69%
1M Prestazione:
+3.64%
6M Prestazione:
+26.40%
1 anno Prestazione:
+20.22%
Intervallo 1D:
$226.25
$229.04
Intervallo di 1 settimana:
$223.10
$232.81
Portata 52W:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
227.99 | 403.22B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
825.45 | 736.03B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.40 | 463.72B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
130.36 | 254.84B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.49 | 217.76B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance
Why AbbVie Inc. (4AB) stock stays on top picksWeekly Trade Report & Weekly Breakout Watchlists - newser.com
AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
Published on: 2025-10-24 20:28:34 - newser.com
AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment? - TipRanks
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - sharewise.com
Is AbbVie Inc. stock a buy on dipsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - sharewise.com
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - The Motley Fool
Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating - MarketScreener
Can AbbVie Inc. stock attract analyst upgradesMarket Risk Report & Reliable Price Breakout Signals - newser.com
Will AbbVie Inc. stock attract more institutional investors2025 Retail Activity & Stepwise Trade Signal Implementation - newser.com
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Insider Monkey
AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey
AbbVie Up More Than 30% in 6 Months: How to Play the Stock - The Globe and Mail
YieldBoost AbbVie From 2.9% To 6.9% Using Options - Nasdaq
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
How sentiment analysis helps forecast AbbVie Inc.Global Markets & Community Trade Idea Sharing Platform - newser.com
Can AbbVie Inc. stock withstand economic slowdownBull Run & Technical Pattern Based Signals - newser.com
Measuring AbbVie Inc.’s beta against major indices2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
How AbbVie Inc. (4AB) stock performs in volatility spikesJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
Will AbbVie Inc. stock outperform Dow JonesInsider Selling & Stepwise Trade Execution Plans - newser.com
Why AbbVie Inc. stock is in analyst buy zoneQuarterly Trade Summary & Daily Entry Point Alerts - newser.com
Can AbbVie Inc. stock surprise markets with earningsTrade Signal Summary & Daily Momentum Trading Reports - newser.com
AbbVie's Rinvoq Beats Humira in Key Arthritis Trial - Yahoo Finance
Fund Update: Bank Pictet & Cie (Europe) AG added 112,421 shares of ABBVIE (ABBV) to their portfolio - Quiver Quantitative
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Alpha Cognition Inc (ACOG) and Exelixis (EXEL) - The Globe and Mail
Bernstein Remains a Hold on AbbVie (ABBV) - The Globe and Mail
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients - AbbVie News Center
How AbbVie Inc. stock compares with tech leadersQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Five things for pharma marketers to know for Tuesday, October 21, 2025 - Medical Marketing and Media
Will AbbVie Inc. stock maintain strong growthRate Cut & High Conviction Buy Zone Alerts - newser.com
How AbbVie Inc. stock performs in rising dollar environment2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 2025Weekly Loss Report & Risk Adjusted Swing Trade Ideas - newser.com
Lobbying Update: $980,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
Is AbbVie Inc. a candidate for recovery play2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com
AbbVie's Rinvoq (ABBV) Outperforms Humira in Key Rheumatoid Arthritis Trial - GuruFocus
AbbVie's Rinvoq beats Humira in head-to-head rheumatoid arthritis trial - Seeking Alpha
AbbVie's Rinvoq shows superiority over Humira in head-to-head arthritis study - Reuters
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressure2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings - sharewise.com
Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com
Guggenheim Raises Price Target for AbbVie (ABBV) to $242 | ABBV Stock News - GuruFocus
AbbVie (ABBV) Reports Positive Phase 3b/4 Study Results for Upad - GuruFocus
AbbVie Says Upadacitinib Shows Superior Efficacy Over Humira in Late-Stage Rheumatoid Arthritis Trial - MarketScreener
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):